Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06066645 · ClinicalTrials.gov registry record · Phase 3
Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone
A Phase 3 study of Glaucoma Open-Angle, sponsored by Glaukos Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 230
- Enrollment target
- 1
- Study location
NCT06066645: Recruiting Phase 3 study of Glaucoma Open-Angle, sponsored by Glaukos Corporation.
NCT06066645 is a Phase 3 study of Glaucoma Open-Angle that is actively recruiting participants, run by Glaukos Corporation. The registered enrollment target is 230 participants, above the 155-participant average among 22 other Glaucoma Open-Angle trials with a reported enrollment target (48% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06066645, a Phase 3 study of Glaucoma Open-Angle, is actively recruiting participants, sponsored by Glaukos Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 230 participants
- Enrollment target
- 1
- Study location
Study Summary
Adult subjects with elevated intraocular pressure who have successfully undergone placement of iStent infinite trabecular bypass system will be randomized to receive a travoprost intraocular implant or receive a sham procedure and be followed for 12 months.
Primary Outcome
mean diurnal IOP at the 3 month visit minus mean diurnal IOP at baseline
Conditions Studied
Interventions
- DRUG Travoprost Intraocular Implant
- OTHER Sham procedure 1
- DEVICE iStent infinite
- OTHER Sham procedure 2
Study Locations (1)
Colorado
- Glaukos Clinical Study Site - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2023-09-14 |
| Est. Completion | 2028-02 |
| Phase | Phase 3 |
What NCT06066645 shows while recruiting
NCT06066645 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, above the 155-participant average among 22 other Glaucoma Open-Angle trials with a reported enrollment target (48% higher).
The record links to 1 condition, with Glaucoma Open-Angle appearing as the primary indexed condition, and to 4 interventions - of which Travoprost Intraocular Implant is the first listed.
NCT06066645 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT06066645 about?
NCT06066645 is a clinical study titled "Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone". Adult subjects with elevated intraocular pressure who have successfully undergone placement of iStent infinite trabecular bypass system will be randomized to receive a travoprost intraocular implant or receive a sham procedure and be followed for 12 months.
What is the current status of trial NCT06066645?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 230 participants. The study started on 2023-09-14. Estimated completion is 2028-02.
What conditions does trial NCT06066645 study?
This clinical trial studies the following conditions: Glaucoma Open-Angle.
What interventions are being tested in trial NCT06066645?
The interventions under investigation include: Travoprost Intraocular Implant (DRUG), Sham procedure 1 (OTHER), iStent infinite (DEVICE), Sham procedure 2 (OTHER).
Who is sponsoring clinical trial NCT06066645?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06066645 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma Open-Angle
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06066645's enrollment target sits among peer trials
230 5th of 22 higher than 18 of 22 other Glaucoma Open-Angle trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma Open-Angle trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RECRUITING · Phase 3
-
Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%
COMPLETED · Phase 3
-
A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)
COMPLETED · Phase 3
-
Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
-
24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring
RECRUITING
-
Electrical Stimulation for Vision Neuroenhancement in Glaucoma
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI